No abstract

SARS-CoV-2 is one of the greatest pandemics in the history. There is no medicine or vaccine yet discovered to control the outbreak. The paper deals with repurposing existing drugs to control the outbreak of SARS-CoV-2 virus.Ten FDA-approved drugs namely Indinavir, Nelfinavir, Letermovir, Irinotecan, Elbasvir, Saquinavir, Darunavir, Raltegravir, Atazanavir and Amprenavir were studied. In silico methods for virtual screening of protein-ligand docking of these drugs against SARS-CoV-2 MPro was performed. The binding efficiency of the drugs against viral main protease MPro was significantly high to inhibit SARS-CoV-2.The results confirmed that Atazanavir, Nelfinavir, and Letermovir not only occupied the active site of Mpro but also showed increased binding affinity (-10.36 kcal/mole, -9.47 kcal/mole and -9.43 kcal/mole) even more than of control drugs of Lopinavir (-8.71 kcal/mole) and Ritonavir (-8.08 kcal/mole). These repurposed drugs can be used in combination or individually as an alternative approach for rapid drug discovery against SARS-CoV-2

Aim- To study the prevalence of Sensorineural Hearing Loss in patients with Diabetes Mellitus and to compare the degree and severity of hearing loss in patients with diabetes controlled on medications with uncontrolled disease Methodology- Prospective observational study was conducted to assess prevalence of sensory-neural hearing loss in patients with diabetes mellitus attending ENT OPD at GRMC Gwalior, Madhya Pradesh, India from December 2020 to May 2022. Auditory function was measured with Pure Tone Audiometry (PTA) Among 280 patients with Diabetes mellitus, Results- 184 patients had Sensory-neural hearing loss (65.70%). As the disease duration increased above 10 years, incidence of SNHL increased to 88.4% in both ears. Sensorineural hearing loss is Conclusionprevalent in 65.71% of type II diabetic patients. Sensorineural hearing loss in diabetes mellitus is usually gradually progressive involving high frequency thresholds. Hearing threshold increases with advanced age and increased duration of diabetes. Patients with poor control [HbA1c greater than 8.5%] of their glycemic status had raised auditory thresholds.